Marizyme, Inc. announced the William Hearl as a director on the Board. Dr. Hearl was nominated by Univest as contractually obligated related to the completion of the recent funding of the Company. On December 1, 2020, the Board of Marizyme appoint Dr. Steven Brooks as Chief Medical Officer and Executive Vice President of Medical and Regulatory Affairs and On December 2, 2020, the Board of Marizyme appointed Dr. Donald Very as Executive Vice President of Research and Development. Dr. Hearl is the founder of Immunomic Therapeutics, Inc. and is an experienced and successful life science businessman and entrepreneur. Dr. Hearl is adept at brokering mutually beneficial partnerships and identifying non-traditional collaborations and investment opportunities. Dr. Brooks is currently the principal of Brooks Medtech, LLC. Previously, Dr. Very served as Senior Vice President of Mosaigen.
Marizyme, Inc. is a medical technology company. The Company is focused on cardiac and surgical care by delivering innovative solutions for coronary artery bypass graft (CABG) surgery and other surgical procedures. Its product DuraGraft, is a one-time intraoperative vascular graft treatment for use in vascular and bypass surgeries that maintains endothelial function and structure, thereby reducing the incidence and complications of graft failure and improving clinical outcomes post bypass surgery. The Companyâs product under development includes MATLOC and MAR-FG-001. MATLOC is a lab-on-chip digital screening and diagnostic device platform being developed for quantitative chronic kidney disease (CKD) assessment. The MAR-FG-001 is a tumescent solution base for fat grafting procedures that is used for plastic and cosmetic surgeries in which fat is transferred from one area of the body to another to correct a defect, replace injured tissue, or to make cosmetic enhancements.
MARIZYME, INC. 
